We Had Seven Days of Cash Left with Dan Rose

In this episode of the Crux of Cardio, Jordan Burgin sits down with Dan Rose, CEO of Endovascular Engineering (E2), to talk about building, exiting, and doing it all over again this time in one of the hottest spaces in cardiovascular medicine.Dan joined LimFlow as its first employee, guided it through an FDA approval, a landmark New England Journal of Medicine publication, and ultimately its acquisition by Inari Medical. Weeks before that deal closed, E2 had seven days of cash in the bank.Key TopicsThe PE thrombectomy market and what the Stryker–Inari and Boston Scientific–Penumbra acquisitions signalBuilding LimFlow from the ground up as a first-time CEO and first employeeWhy changing physician behaviour is harder than building the technologyCultivating strategic relationships before you need themManaging strategics on your cap table without compromising board integrityWhat physicians actually want from the next generation of PE devicesClosing an oversubscribed $80M Series C when most of the market is starved for capitalThe role of chair seats in extending a CEO's impact and perspectiveRelated InsightsWhy market development, not efficacy is often the real barrier to adoptionThe emotional reality of exits: the post-acquisition dip no one talks aboutWhy CEOs should proactively build peer networks and ask for helpHow arriving second in a category can be a structural advantage if you have differentiated technologyThe value of transatlantic commercial experience in European medtechCore ChallengesPulmonary embolism is the third leading cause of cardiovascular death, yet the current category leaders are delivering incremental innovation rather than the low-profile, high-efficiency, blood-return-capable devices physicians are asking for.Medtech startups moving into unfamiliar physician behaviour, like foot-focused wound care for interventional cardiologists at LimFlow, require deep clinical education infrastructure, not just compelling data.Founder CEOs face a lonely role where they cannot be fully transparent with their own teams, and must actively build external peer networks to stay effective and grounded.🎧 Tune in now to hear what it really takes to build, exit, and rebuild in medtech and why Dan Rose had just seven days of cash left when the LimFlow deal finally closed.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠